Tracking quality of life and relapses in bladder cancer patients after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects data from adult patients who have undergone endoscopic resection surgeries for non-muscle invasive bladder cancer. Patients will be followed for approximately 10 years, with yearly follow-ups conducted via phone, email, or mail to gather information on their health status and quality of life. Data will be meticulously recorded in a secure database, adhering to strict guidelines for privacy and good clinical practices. The study aims to understand the occurrence of relapses and the overall quality of life in these patients over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years or older
* Patients with non-muscle invasive bladder cancer
* Indication to cancer removal through endoscopic resection surgery
* Ability to read and sign the informed consent

Exclusion Criteria:

* Age \<18 years
* Inability to read and sign the informed consent

Where it's running

• IRCCS Ospedale San Raffaele
  Milan, Mi, Italy Recruiting

Study contacts

• Principal investigator: Francesco Montorsi, MD — IRCCS Ospedale San Raffaele
• Study coordinator: Francesco Montorsi, MD
• Email: montorsi.francesco@hsr.it
• Phone: +390226437286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• New combination therapy for HER2-positive muscle-invasive bladder cancer

  A phase 2, multi-center study tests four sensitizing drugs with disitamab vedotin and toripalimab in adults with HER2-positive muscle-invasive bladder cancer to see if the treatment can lead to tumor reduction and potential bladder preservation.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07717242

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

• Comparing CT and MRI with VI-RADS for Bladder Cancer Staging

  This study tests how well CT and MRI with VI-RADS can correctly stage bladder cancer before surgery in adults.

  Recruiting Oslo University Hospital · Oslo · NCT07602010

• Ureteral stent versus no stent for adults having radical cystectomy with an ileal conduit

  This trial tests whether placing temporary ureteral stents at the time of radical cystectomy with ileal conduit reduces post-operative complications compared with not placing stents in adults having cystectomy for bladder or other pelvic cancers.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania and 1 other locations · NCT07234968

• AI-enhanced blue light cystoscopy for bladder cancer detection

  This project will collect blue light cystoscopy videos from adults having Hexvix/Cysview-enhanced cystoscopy and test AI tools to help doctors better find bladder cancer during the procedure.

  Recruiting at 12 sites Photocure · Tampa, Florida and 11 other locations · NCT07144319

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.